Loading...
OTCM
ELTP
Market cap397mUSD
Jul 09, Last price  
0.37USD
1D
-0.62%
1Q
-3.47%
Jan 2017
141.25%
IPO
-10.56%
Name

Elite Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ELTP chart
P/E
8.80
P/S
2.65
EPS
0.04
Div Yield, %
Shrs. gr., 5y
3.84%
Rev. gr., 5y
42.45%
Revenues
149m
+77.13%
1,143,8411,413,1192,274,8253,344,2984,265,9632,424,1183,403,5254,601,3765,015,24612,498,3329,637,7157,458,7117,568,50817,994,63925,380,74932,262,11734,155,11456,625,12884,043,929148,870,119
Net income
45m
P
-11,803,512-13,893,060-6,604,708-8,056,874-13,582,159-15,058,2741,487,928-96,575,27128,929,674-683,0123,811,181-3,673,172-9,279,321-2,240,3515,088,4218,898,2454,409,90220,108,631-4,314,65944,872,686
CFO
23.75b
+318,425.27%
-8,314,268-9,834,277-4,540,068-1,364,7481,552,815-394,082-1,943,409-4,216,875-15,103,233-2,765,421-7,883,861-4,809,191-6,792,760-1,793,8213,193,8616,508,3143,338,704-3,281,5587,455,63923,748,094,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
IPO date
Feb 20, 2014
Employees
53
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT